Instructions for Duoresp Spiromax (Budesonide, Formoterol) powder with an inhaler
English Product Name
DuoResp Spiromax
Brief description
Bronchodilating combination drug (selective beta2-adrenomimetic + glucocorticosteroid).
Testimony Duoresp Spiromax:
- Bronchial asthma, insufficiently controlled by inhalation GCS and short-acting beta2-adrenomimetics as on-demand
- therapy or adequately controlled by inhalation GCS and long-acting beta2-adrenomimetics;
- COPD is a symptomatic therapy in patients with severe COPD with postbronchodilatory OFV1 of less than 70% of due
- duration and with exacerbations in the history, despite regular treatment with long-acting bronchodilators.
Contraindications Duoresp Spiromax:
Increased sensitivity to budesonide, formoterol or inhalable lactose;
lactose intolerance, lactase deficiency or glucose-galactic malabsorption;
the age is up to eight years old.
With caution: pulmonary tuberculosis (active or inactive form), fungal, viral or bacterial respiratory infections, thyrotoxicosis, pheochromocytoma, diabetes mellitus, adrenal cortex dysfunction, uncontrolled hypokalemia, idiopathic hypertrophic subaortic stenosis, severe arterial hypertension, aneurysm of any location or other severe cardiovascular diseases (IBS, tachyarrhythmia or severe heart failure), lengthening of the QT interval (ingestion of formoterol can cause lengthening of the QT interval).
Pharmacological effect:
Spiromax duoRep contains formoterol and budesonide, which have different mechanisms of action and have an additive effect in reducing the frequency of exacerbations of bronchial asthma and COPD.
Budesonide + Formoterol
Bronchial asthma
Adding formotherol to budesonide reduces the severity of bronchial asthma symptoms, improves bronchial function, and reduces the frequency of disease exacerbations.
The effect of DuoRep Spiromax on bronchial function corresponds to the action of budesonide and formoterol monotherapies and exceeds the action of one budesonide. In all cases, a short-acting beta-2 adrenostimulator was used to control seizures. There has been no decrease in antiasthmatic action over time. The drug has good tolerability.
The drug, as a maintenance therapy in combination with short-acting beta2 adrenomimetics to control seizures, was administered to patients aged six to 11 for twelve weeks (two 80/4.5 μg/inhalation twice daily). Improvements in pulmonary function and tolerability of the therapy were noted in comparison with the corresponding dose of budesonide in inhalation from the Turbuchaler delivery system.
Constitution Duoresp Spiromax
A powder for inhalation dosed white or almost white, without visible bumps or turns; The indicator window shall show #60.
1 dose delivered
budesonide (micronized) 320 ug
Fumarat dihydrate (micronized) 9 ug
Auxiliary substances: Lactose monogidrat - 10 mg*.
